Why the study?
Immune checkpoint inhibitor-associated cardiotoxicity is a significant cause of mortality lacking effective preventative or therapeutic strategies, prompting investigation of Xihuang Pill.
Does Xihuang Pill improve cardiac function and reduce injury markers in a mouse model of immune checkpoint inhibitor-associated myocarditis?
Does Xihuang Pill improve cardiac function and reduce injury markers in a mouse model of immune checkpoint inhibitor-associated myocarditis?
Xihuang Pill mitigates immune checkpoint inhibitor-associated myocarditis in a mouse model by improving cardiac function and reducing injury markers via modulation of the HIF-1 signaling pathway.
Answers are grounded in this paper and cite their sources.
XHW attenuates ICIs myocarditis in mice; leaves open clinical translation and human trials.
Background: Immune checkpoint inhibitor (ICIs)-associated cardiotoxicity is a significant cause of immune-related adverse events and mortality in cancer immunotherapy, lacking effective preventative or therapeutic strategies. Xihuang Pill (XHW), a traditional Chinese medicine with established anti-inflammatory properties and clinical use in cancer treatment and adverse event mitigation, merits investigation for its efficacy against ICIs-induced cardiac toxicity. Purpose: To investigate XHW’s therapeutic effects on Immune checkpoint inhibitors (ICIs)-associated cardiotoxicity and its underlying mechanisms. Methods: This study utilized mass spectrometry technology to identify the chemical components in XHW. The experimental model for ICIs-associated myocarditis was generated in BALB/c mice by immunizing them with murine cardiac troponin I (cTnI) peptide and administering anti-programmed death 1 (PD-1) antibodies to mice. Mice received varying XHW dosages (0.39, 0.78, and 1.56 mg/kg). Myocardial contractility and plasma cardiac injury markers (CK, CK-MB) were assessed. Metabolomics and transcriptomics identified key signaling pathways modulated by XHW, validated via real-time quantitative PCR (QT-PCR). In addition, a correlation analysis was conducted between key genes and differential metabolites. Results: Mass spectrometry identified 171 components in XHW. Pharmacological studies demonstrated that XHW improved cardiac contractility, reduced plasma cardiac injury biomarkers, and attenuated myocardial injury in the myocarditis model. Integrated metabolomic and transcriptomic analyses revealed that XHW primarily modulates the HIF-1 signaling pathway, significantly upregulating HIF-1 mRNA expression and downregulating the mRNA expression of Nppa, Angpt1, Angpt2 , and Trf . Correlation analysis identified significant associations between 16 metabolites, including 13-tetradecynoic acid, 1-pentadecanoylglycerol, and arginyl-glycyl-aspartic acid, and these genes. Conclusion: These findings suggest that XHW may alleviate ICIs-associated myocarditis via HIF-1 signaling pathway, offering a promising therapeutic approach for ICIs-related cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: